GWM
BCLI

Geneos Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Geneos Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-673
Closed -$40K – 2759
2021
Q4 		$40K Buy
+673
New +$33.1K ﹤0.01% 1568
2020
Q4 		– Sell
-7
Closed -$1K – 2893
2020
Q3 		$1K Buy
+7
New +$1.43K ﹤0.01% 2488
2020
Q2 		– Sell
-33
Closed -$2K – 2564
2020
Q1 		$2K Buy
+33
New +$2.58K ﹤0.01% 2231

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Geneos Wealth Management's BCLI Position: Q1 2022 in Review

Geneos Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2022, closing a stake of 673 shares — an estimated $40K sold.

Geneos Wealth Management first reported a position in BCLI in Q1 2020 and held it in 3 quarters. The position peaked at $40K in Q4 2021. 39 funds tracked by Wall St. Rank hold BCLI as of Q1 2022.

  • Geneos Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 673 BRAINSTORM CELL THERAPUTC shares in Q1 2022, an estimated $40K.
  • Geneos Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 3 quarters.
  • Geneos Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $40K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.